Japan Oncology Clinical Trials Market Report 2022 to 2030

Japan Oncology Clinical Trials Market Analysis

$ 3999

Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by a well-established healthcare system, advanced infrastructure, and a high prevalence of cancer. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Chugai Pharmaceutical Co., Ltd. & Ono Pharmaceutical Co., Ltd.

ID: IN10JPCT006 CATEGORY: Clinical Trials GEOGRAPHY: Japan AUTHOR: Vidhi Upadhyay

Buy Now

Japan Oncology Clinical Trials Market Executive Summary

Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. Japan is one of the world's major pharmaceutical markets, accounting for around 7% of worldwide sales. The anti-cancer medicine market is one such area of development in Japan, as it is elsewhere. The oncology market is expected to increase at a 5.2% CAGR through 2026. Cancer is one of Japan's top three major causes of death, and the government is progressively emphasizing patient-centered cancer research and treatment, most notably via the third iteration of the national Basic Plan to Promote Cancer Control. In Japan, there were 1,028,658 new cases of cancer as per the data by Globocan 2020.

Clinical trials are primarily concerned with the development of novel medications, treatments, and therapies for different stages and forms of cancer. Japan has been especially active in conducting clinical trials for lung cancer, the country's one of the largest causes of cancer-related mortality, as well as other prevalent malignancies such as breast, colorectal, and pancreatic cancer. The nation has also been at the forefront of developing novel cancer therapies such as immunotherapy and targeted therapy, as well as conducting clinical trials in these areas.

Japan is one of the world's top nations for oncology clinical trials. Because of its well-established healthcare system, modern infrastructure, and high cancer incidence, a nation is an appealing place for clinical research. Japan has also adopted a number of regulatory changes in recent years in order to expedite the clinical trial process and encourage more international investment in the pharmaceutical business.

japan oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

The country's developed healthcare system, high cancer incidence, legislative changes, robust research infrastructure, and innovative collaborations. Because of the high prevalence of cancer, especially among the elderly, Japan has a huge patient pool. With simplified clinical trial protocols and an established body to examine and approve pharmaceuticals and medical devices, the country's regulatory framework is also advantageous for clinical research. Moreover, the Japanese government supports and funds oncology clinical trials, attracting both local and foreign pharmaceutical firms to participate in the country's clinical research. Additionally, Japan's highly skilled experts and excellent technology make it an attractive venue for clinical studies.

Market Restraints

There are several constraints that may impede the expansion of oncology clinical trials in Japan. One barrier is the aging population, which may result in a smaller patient pool and make recruiting patients for clinical trials more challenging. Another barrier that smaller pharmaceutical businesses may face is the high expense of performing clinical trials in Japan. Moreover, linguistic and cultural barriers may make conducting clinical trials in Japan complicated for international organizations. Third, there is competition from other nations like as China and South Korea, who are both significantly investing in oncology clinical research and may entice investment away from Japan.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
AstraZeneca PLC
Merck & Co., Inc.
Bristol Myers Squibb Co.
Roche Holding AG
Chugai Pharmaceutical Co., Ltd. (JPN)
Daiichi Sankyo Company, Limited (JPN)
Eisai Co., Ltd. (JPN)
Kyowa Kirin Co., Ltd. (JPN)
Ono Pharmaceutical Co., Ltd. (JPN)
Shionogi & Co., Ltd. (JPN)

Notable Insights

In November 2022, Daiichi Sankyo's breast cancer therapy has been approved by Japan's MHLW. The approval was based on the results of Enhertu's Phase III DESTINY-Breast03 study
September 2022, Merck, also known as MSD, said that its anti-PD-1 medication KEYTRUDA gained four additional approvals from Japan's Ministry of Health, Labor, and Welfare (MHLW) Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
March 2022, CIRCULATE-Japan Colorectal Cancer Findings were updated. The CIRCULATE-Japan trial is a three-arm study of patients with stage II and III colon or rectal cancer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Japan's Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.